PET Scan for Cancer Follow-Up: Can It Show Whether Treatment Is Working?

 

A PET scan for cancer can play an important role in follow-up care by showing how active a tumour appears after treatment. It may help doctors assess whether cancer has responded, remained stable, progressed or returned. However, a PET scan is not interpreted in isolation. Specialists compare it with previous scans, CT or MRI findings, symptoms, blood tests and the type and timing of treatment.

For patients treated with surgery, chemotherapy, immunotherapy, targeted therapy, conventional radiation or CyberKnife S7, follow-up imaging helps guide the next stage of care. A PET scan can provide valuable information, but it does not always give an immediate or final answer about whether treatment has worked.

What Is a PET Scan for Cancer?

PET stands for positron emission tomography. In oncology, a PET scan is frequently combined with CT imaging, creating a PET-CT scan. The CT scan shows the body’s anatomy, including tumour size and location, while the PET component shows metabolic activity.

Most cancer PET scans use a small amount of radioactive glucose-like tracer called fluorodeoxyglucose, or FDG. Cancer cells often use more glucose than normal cells because they may grow and divide more rapidly. Areas that take up more FDG can appear as “hot spots” on the scan.

A PET-CT can therefore provide two types of information:

• Structural information: Where a mass, lymph node or lesion is located and whether it has changed in size.

• Metabolic information: Whether a suspicious area is using more glucose than surrounding tissue.

PET/CT can support cancer diagnosis, staging, restaging, treatment-response assessment and surveillance in appropriately selected patients.

It is important to remember that increased FDG uptake is not proof of cancer by itself. Infection, inflammation, healing tissues and some non-cancerous conditions may also show increased tracer uptake.

Can a PET Scan Show if Treatment Is Working?

Yes, a PET scan for cancer can often help determine whether treatment is working, particularly when compared with a baseline scan performed before treatment. Doctors look for changes in metabolic activity, tumour size, spread to lymph nodes or distant organs, and the appearance of new suspicious areas.

A favourable response may include:

• Reduced FDG uptake within the treated tumour.

• Shrinkage of the tumour on CT or MRI.

• Fewer metabolically active lymph nodes or metastatic lesions.

• No new sites of disease.

• Stable disease when the tumour has not grown or become more metabolically active.

If a lesion shows lower metabolic activity after treatment, it may suggest that the cancer cells are responding. In some cancers, metabolic changes can occur before a clear reduction in tumour size is visible. This makes PET useful in certain treatment-response situations.

Reliable assessment requires comparison with a pre-treatment baseline scan whenever possible. PET response interpretation must also consider tumour type, treatment method and the timing of the scan.

However, a scan cannot always show the full answer immediately. Some tumours shrink slowly, while others leave scar tissue or inactive tissue behind. A residual mass does not necessarily mean active cancer is still present.

PET Scan After CyberKnife S7 Treatment

CyberKnife S7 is an advanced robotic radiation therapy system that delivers focused radiation to selected tumours. It may be used for carefully chosen brain, lung, liver, spine, prostate, pancreas and other tumour cases.

After cyberknife treatment, imaging is necessary to assess the treated area over time. A PET scan may be used in selected cases, particularly for cancers where FDG PET-CT is clinically useful, such as many lung, head-and-neck, lymphoma and metastatic cancers.

CyberKnife S7 is designed to deliver highly targeted radiation with sub-millimetre precision. At Valentis Cancer Hospital, the system is used for personalised treatment planning for selected cancer and complex tumour cases.valentiscancerhospital+1

The response after radiation can be gradual. The treated tumour may remain visible on a CT scan or MRI for some time. It may become smaller slowly, remain stable or develop scar-like changes. PET imaging can add information about metabolic activity, but radiation-induced inflammation may temporarily increase FDG uptake and make the area appear more active than it truly is.

For this reason, a PET scan performed too soon after radiation may be difficult to interpret. The Society of Nuclear Medicine and Molecular Imaging notes that increased FDG uptake can occur in recently irradiated tissue and may persist for 12 to 16 weeks.

Why Timing Is Important

The timing of a PET scan for cancer follow-up depends on the cancer type and treatment received. An early scan can sometimes be misleading because healing and inflammation can mimic tumour activity.

For treatment-response evaluation after radiation therapy, PET findings are often more reliable when imaging is delayed. One clinical review notes that response assessments after radiotherapy are generally most reliable around 8 to 12 weeks after treatment completion.

For post-radiation response assessment, the SNMMI recommends considering the first PET-CT at least 12 weeks after radiation therapy, helping reduce false-positive results caused by radiation-related inflammation. For chemotherapy, imaging is commonly timed at least three weeks after treatment completion, though the treating oncologist decides the appropriate schedule for each patient.

The schedule may be different for patients receiving immunotherapy. Some patients can develop pseudoprogression, where immune-cell activity makes lesions look larger or more active before a later response occurs. This pattern has been reported in a small percentage of people receiving immune checkpoint inhibitors,

What Results Can Mean

A PET report should always be discussed with an oncologist or nuclear medicine specialist. Common outcomes may include:

Standardised response criteria also require correlation between PET and anatomical imaging. Under RECIST 1.1, a PET “hot spot” should be correlated with CT or MRI findings before it is used to confirm progressive disease.

PET Scan Test Cost and Factors

The pet scan test cost can vary based on the city, hospital, type of tracer, body area scanned, use of contrast, need for specialised imaging and whether the patient requires additional investigations.

In India, patients should request a written estimate that clearly explains what is included. The cost may cover:

• Radiotracer preparation and injection.

• PET-CT scanning.

• Radiologist or nuclear medicine reporting.

• Contrast material, if clinically required.

• Blood sugar assessment before FDG PET.

• Follow-up consultation with the oncologist.

Patients with diabetes should inform the imaging team in advance because blood glucose levels can affect FDG PET scan quality and interpretation.

What Patients Should Do Next

A PET scan for cancer is a valuable follow-up tool, but it is one part of a larger clinical picture. The best assessment includes imaging comparison, pathology reports, tumour markers where relevant, physical examination and the patient’s symptoms.

At Valentis Cancer Hospital, PET-CT can support treatment planning and follow-up for eligible patients receiving CyberKnife S7 and other cancer therapies. The oncology team reviews imaging findings in context to decide whether observation, further scans, biopsy, additional local therapy or systemic treatment is appropriate.

The key message is simple: a PET scan can show important signs of treatment response, but it must be timed correctly and interpreted by specialists. A single scan result should not create unnecessary fear or false reassurance without clinical correlation.